This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Deep-Dive into Efruxifermin as a therapy for nonalcoholic steatohepatitis
Ticker(s): AKROWho's the expert?
Institution: Arizona Liver Health (ALH)
- The VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ.
- Treats 1000 patients with NASH.
- Fellowship trained (Adult Transplant Hepatology) at the Cleveland Clinic.
- Specializes in nonalcoholic fatty liver disease, viral hepatitis, autoimmune hepatitis, alpha 1 antitrypsin deficiency, and liver transplantation; has over 160 publications and presents his work at both national and international medical conferences.
Interview GoalThis conversation will focus on the NASH treatment landscape with a focus on the recent data from Akero's HARMONY Phase IIb trial for efruxifermin.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
